Correct Answer: D. RNA editing
Apolipoprotein B (apoB) synthesis uniquely involves RNA editing, a post-transcriptional modification that generates two distinct proteins from a single gene. The APOB gene encodes a 4536-codon mRNA that is transcribed normally. However, in the intestine, a cytidine deaminase enzyme (APOBEC1) catalyzes the deamination of cytidine to uridine at position 6666 of the apoB mRNA. This C-to-U conversion changes the codon CAA (glutamine) to UAA (stop codon), resulting in premature termination and synthesis of apoB48 (48% of full-length apoB). In contrast, the liver produces full-length apoB100 because the editing enzyme is absent or inactive there. This mechanism is crucial for lipid transport: apoB48 is essential for chylomicron assembly in intestinal enterocytes, while apoB100 is required for VLDL and LDL formation in hepatocytes. The editing process occurs post-transcriptionally on the mature mRNA, making it distinct from splicing or DNA-level modifications. This is a classic example of regulated RNA editing and is a high-yield concept for NEET PG biochemistry.
Why the other options are wrong
A. RNA interference — RNA interference (RNAi) involves silencing of gene expression through small interfering RNAs (siRNAs) or microRNAs that degrade or block translation of target mRNAs. It does not generate structural variants of proteins from a single transcript. ApoB48 is generated by a specific nucleotide modification, not by RNA degradation or translational silencing. B. RNA alternate splicing — Alternate splicing involves selective inclusion or exclusion of exons during pre-mRNA processing to generate multiple protein isoforms. While apoB does undergo some splicing, the critical distinction between apoB48 and apoB100 is NOT due to exon skipping but rather due to C-to-U editing that creates a stop codon. Splicing alone cannot explain the tissue-specific generation of apoB48. C. DNA editing — DNA editing would imply permanent changes to the genomic DNA sequence, which would be heritable and affect all cells. ApoB48 synthesis is a reversible, post-transcriptional process that occurs only in intestinal cells and does not alter the underlying DNA. The same APOB gene produces different proteins in different tissues based on RNA editing, not DNA modification.
High-Yield Facts
- ApoB48 is generated by C-to-U RNA editing at position 6666 of apoB mRNA, converting CAA (Gln) to UAA (stop), resulting in 48% of full-length protein.
- APOBEC1 (cytidine deaminase) is the enzyme responsible for apoB48 editing; it is active in intestine but absent/inactive in liver, explaining tissue-specific isoform production.
- ApoB48 is essential for chylomicron assembly in enterocytes; apoB100 is required for VLDL/LDL synthesis in hepatocytes—same gene, different lipoproteins.
- RNA editing is a post-transcriptional modification occurring on mature mRNA, distinct from splicing (pre-mRNA) and DNA-level changes.
- The apoB editing mechanism is conserved across mammals and is one of the few known examples of regulated C-to-U RNA editing in humans.
Mnemonics
ApoB48 = C-to-U Editing Cytidine → Uridine deamination by APOBEC1 creates a stop codon (UAA) in intestine only. Remember: Cytidine in Colon/intestine → Uridine = stop. **Intestine = Isoform (apoB48); Liver = Long (apoB100)** Intestine produces short apoB48 via editing; Liver produces full-length apoB100 without editing. Use initial letters to anchor tissue-specific isoforms.
NBE Trap
NBE may pair "RNA splicing" with apoB to trap students who confuse post-transcriptional modifications. While some splicing does occur in apoB processing, the defining mechanism for apoB48 generation is C-to-U editing, not exon skipping.
Clinical Pearl
In Indian patients with familial hypercholesterolemia or dyslipidemia, understanding apoB isoforms is critical: defective apoB100 impairs LDL clearance (hepatic), while apoB48 defects cause fat malabsorption. Genetic variants in APOBEC1 or APOB can alter the editing efficiency, affecting lipid profiles and cardiovascular risk in the Indian population.
_Reference: Harper Biochemistry Ch. 28 (Lipid Transport); KD Tripathi Pharmacology Ch. 25 (Lipid-Lowering Drugs)_